Developing AI-Based Assessments for TIL Scoring in Melanoma and Beyond
Artificial intelligence used in conjunction with clinicians may help standardize and expedite pathology workflows and reduce variability in TIL scoring.
Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC
No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.
PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer
Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.
Subcutaneous Daratumumab Provides “Win-Win” in NDMM Maintenance
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer
Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.
Acknowledging Mortality and Death in Cancer Care
In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.
Are Novel Immunotherapy Combos Effective for Indolent Lymphoma Care?
Bispecific antibodies have demonstrated adaptability and versatility when combined with immunotherapy and chemotherapy agents.
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup
Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.
Certepetide/FOLFIRINOX Displays Encouraging Preliminary Feasibility in PDAC
The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
Scaling Immune Cell Quantification in Melanoma Through AI-Driven Assessment
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS
An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.
Overcoming the “Nihilism” Surrounding the Small Cell Lung Cancer Prognosis
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care
Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.
The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma
Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.
Optimizing Surveillance and Counseling for BCG-Unresponsive Bladder Cancer
Gary Steinberg, MD, discusses the role of patient counseling and surveillance when using the gemcitabine intravesical system for BCG-unresponsive NMIBC.
Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL
An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.
Managing Toxicities in BCMA/GPRC5D-Directed Therapies in Multiple Myeloma
CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.
Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML
Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer
Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.
Multidisciplinary Team Discusses Practical Treatment Options in NSCLC
Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.
Highlighting Operational Challenges in the AML Treatment Landscape
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations
Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.
FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer
Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.
Oral Agents Provide Greater Acute Myeloid Leukemia Treatment Diversity
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Episode 15: Applying ctDNA Practically to Cancer Research and Management
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Diving Into the Practical Applications of ctDNA in Oncology Care
Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.
Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
Atebimetinib with gemcitabine and nab-paclitaxel achieved 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.
Understanding “Paradigm-Changing” Events in Small Cell Lung Cancer Care
The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.
Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC
In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.
